TY - JOUR
T1 - THe centers for medicare & medicaid services and amyloid-β positron emission tomography for alzheimer disease
AU - Steinbrook R
Y1 - 2014/01/01
N1 - 10.1001/jamainternmed.2013.11705
JO - JAMA Internal Medicine
SP - 135
EP - 135
VL - 174
IS - 1
N2 -
In July 2013, the CMS issued a draft decision for public comment about the use of Aβ PET,1 proposing “that the evidence is insufficient to conclude that the use of [Aβ PET] imaging improves health outcomes for Medicare beneficiaries with dementia or neurodegenerative disease.” In this issue of JAMA Internal Medicine, Pearson and colleagues at the Institute for Clinical and Economic Review summarize their review2 of the evidence for the imaging in the diagnostic evaluation of AD. They found that “the medical literature provides extremely limited data with which to evaluate the clinical utility of Aβ PET.” Their review was part of the background material for CMS’s technology assessment of the current status of the scans.1
SN - 2168-6106
M3 - doi: 10.1001/jamainternmed.2013.11705
UR - http://dx.doi.org/10.1001/jamainternmed.2013.11705
ER -